WuXi Biologics Recognized for Two Decades of Sustainability Efforts by UN Global Compact

WuXi Biologics Acknowledged by UN Global Compact for Sustainability Impact

In December 2024, WuXi Biologics, renowned as a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced its recognition in the report titled "20 Case Examples for 20 Years Private Sector's Sustainable Development in China" by the United Nations Global Compact (UNGC). This honor comes as part of a series of events marking the UN Global Compact's 20th anniversary of promoting Environmental, Social, and Governance (ESG) practices globally. The UNGC focuses on showcasing exemplary practices among firms committed to sustainable development, thereby sharing innovative approaches with a broader audience.

The report aims not only to exhibit successful sustainability initiatives but also to highlight the ongoing transformation occurring within the corporate landscape towards more responsible governance. According to Sanda Ojambo, Assistant Secretary-General of the UN Global Compact, companies selected for this collection exemplify a unique dedication to aligning economic ambitions with social responsibility and environmental stewardship. They collectively showcase the potential for businesses to maintain profitability while also embedding sustainable practices into their operations.

Dr. Chris Chen, CEO of WuXi Biologics, expressed gratitude for the recognition, emphasizing their commitment to innovation alongside sustainability. He noted how WuXi Biologics remains committed to delivering comprehensive green biologics solutions across the industry. This includes substantial investments in green research, development, and manufacturing processes aimed at reducing environmental impacts, thus helping global partners meet their sustainability goals.

WuXi Biologics differentiates itself with its pioneering technologies, including the WuXiBody™ for universal bispecific antibodies, WuXiUI™ for ultra-intensified fed-batch production, and WuXiUP™ for ultra-high productivity continuous processing. These platforms enable it to achieve enhanced productivity while significantly minimizing carbon footprints through the reduction of energy and resource consumption.

In recent years, WuXi Biologics has also garnered prestigious accolades for its sustainability endeavors. They received an AAA rating from MSCI ESG Ratings consistently for two years, were included in both the DJSI World Index and Emerging Markets Index, and earned the Platinum Medal from EcoVadis for sustainability excellence. Additionally, the company has been recognized by Sustainalytics and selected as a constituent of the FTSE4Good Index Series.

Moreover, WuXi Biologics actively participates in a variety of global initiatives aimed at furthering the United Nations Sustainable Development Goals (SDGs), further integrating green technology into its operations. As an active advocate for green practices, WuXi Biologics continuously strives to develop sustainable solutions that benefit clients and the environment across its operational spectrum.

The UNGC's report serves as an essential reminder to the industry about the role of corporate leadership in sustainable development against a backdrop of pressing global challenges, including climate change, resource scarcity, and social inequality. By showcasing successful case studies, companies like WuXi Biologics exemplify how persistent commitment to ESG practices can elevate corporate reputation while genuinely contributing to a better world.

Through diverse partnerships and shared strategies, WuXi Biologics is dedicated to propelling the CRDMO sector towards a more sustainable future. The recognition by UNGC reinforces the ongoing efforts of WuXi Biologics to innovate responsibly while ensuring that the fundamental pillars of sustainability—environmental health, social equity, and economic viability—remain at the forefront of its business model.